Voiant Hub 2.0 is the newest version of Voiant trusted platform that is set to transform the industry. At the core of this innovation is Voiant ReadReady™, a proprietary image flow optimization process developed by Voiant AI Lab. ReadReady™ leverages artificial intelligence to automate quality control and image preparation, eliminating manual steps and accelerating time from intake to read.
Voiant announced the release of Voiant Hub 2.0 at the 2025 ASCO Annual Meeting. Voiant Hub, a fully 21 CFR Part 11 compliant imaging next -generation platform, is designed to support every stage of clinical imaging endpoint data delivery—from image upload to query management, data analysis, and final reporting.
Built for the complexity of modern clinical trials, Voiant-Hub offers a fully configurable, AI-powered, and highly scalable solution that can be accessed from any device, anywhere. Its collaborative architecture enables seamless interaction between sites, readers, and sponsors within a single, secure platform.
Voiant Hub 2.0 is the newest version of Voiant trusted platform that is set to transform the industry. At the core of this innovation is Voiant ReadReady™, a proprietary image flow optimization process developed by Voiant AI Lab. ReadReady™ leverages artificial intelligence to automate quality control and image preparation, eliminating manual steps and accelerating time from intake to read.
Also Read: Basil Launches AI Tool to Boost Pharma Labeling & Insights
“Voiant Hub 2.0 was built with a clear purpose: to break through the inefficiencies of legacy imaging platforms,” said Bharath Ramakrishna, Sr. VP of Product and Innovation. “With this release, we are delivering the power of AI directly into the imaging workflow, empowering teams to make faster decisions with greater confidence. We are proud to set a new industry benchmark for imaging speed, accuracy, and compliance”.
This AI-powered automation compresses the average image turnaround time from days to minutes, providing near-instant readiness for reader review and accelerating time to insight for sponsors, making it the ideal tool for rapid decision such as patient eligibility or treatment decisions.
Additional features specifically adapted to Oncology clinical trials were also part of this new release. Voiant ReadReady™ enables semi-automated RECIST and RANO, as it performs anatomy coverage checks, contrast detection, DICOM validation, organ segmentation, and lesion contouring—all within minutes of image upload. Other radiomic features included volume, shape, intensity, texture, and lesion heterogeneity. These biomarkers offer valuable insights into tumor characteristics and behavior, supporting the development of more effective treatment strategies and improving patient outcomes.
Source: PRweb
